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Introduction 
 
The dual-enrolling of phase 1 volunteers is a potential risk to subjects.  It can 
also distort study results, threaten study validity, and may cause harm to future 
patients.  Existing subject registries differ in structure, funding, and governance.  
While the choice of the ideal system is driven by the scope of the risk, funding 
mechanism, and is ultimately a value judgment of freedom vs. paternalism, none 
of the registries significantly impinges on the tenets of ethically based research. 
 
 
The Belmont report, issued in 1978 by the National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Research, identified 
key pillars of ethical research to be justice, autonomy and beneficence.  A key 
principal is that human subject research has a responsibility to minimize harm 
and maximize benefit for participants as long as there is acceptable equipoise.  
There is, however, no absolute requirement of potential benefit for participation 
for even those with disease.  For example, while oncologists and patients 
participate in phase 1 oncology trials with a primary hope for therapeutic 
response, a primary goal of these studies is not necessarily drug efficacy. The 
lack of understanding of the distinction by patients is well described.  Other study 
designs, such as those of non-inferiority or comparative effectiveness, do not 
provide patients with a direct benefit of participation, outside of access to care 
and or financial compensation.  Healthy volunteer studies entail risk, with no 
potential for therapeutic benefit to participants.  The lack of any potential health 
benefit outside of an evaluation of health status has often led to heightened 
Institutional Review Board (IRB) scrutiny for phase 1 studies.  The focus of 
regulation in healthy volunteer clinical trials is typically of the short-term 
protection of subjects from harm directly related to study procedures. Outside of 
cumulative limits on radiation exposure, the role of the subject outside of an 
individual trial is generally not considered.  The National Institutes of Health and 
Federal Drug Administration do not strictly limit the number of studies in which a 
volunteer can participate.  It is suggested merely that subjects should not 
consecutively enroll in studies without adequate time for washout of drug or 
intervention based upon the biology of the system.  Recent attention, however, 
has been raised about the potential of phase 1 volunteer participants to enroll in 
multiple concurrent clinical trials, with calls for a mandatory registry to track 
subjects.(1) 
 
Motivations for healthy volunteer participants in clinical research can be altruistic, 
especially for disease-specific activists or those with afflicted family members.  
For the most part, however, the prime motivation for most phase 1 trial enrollees 
who lack of an underlying disease is in the financial compensation for 
participation.(2,3) Pursuit of compensation can incentivize subjects to enroll in 
multiple studies, despite the potential for personal injury, or risk of discovery and 
loss of access to participate at research sites.  The ease of access to clinical 
research unit web sites which list study calendars, and user-generated 
publications allows subjects to remotely plan participation and allow overlap while 
minimizing study procedure conflict and detection by a clinical research site.  
Because of the ease of access, enrolling in more than one study at a time is a 
problematic issue not only for the sites to identify but also for the safety of 
individual subjects. Multiple enrollment introduces occult bias, primarily by an 
increased incidence of adverse events and drug interactions which may alter 
pharmacokinetic or pharmacodynamic endpoints.  These potential drug 
interactions also clearly increase the personal risk for healthy study subjects.  
The loss of study validity could be seen by subjects in a narrow sense only 
harming a commercial sponsor without larger implications.  However, outside of 
the personal risk subjects take on from dual enrolling, the practice entails 
potential to harm future patients.  In the worst case, the unwarranted maligning of 
a drug due to an undisclosed drug interaction could delay the advancement of 
promising drug candidates, or place restrictions on future use.  Investigating 
adverse events or unexpected results caused by dual enrolling utilizes 
investigator and sponsor resources and is a friction upon the system that detracts 
from the development of other drugs. 
 
A number of countries have approached the problem of dual enrollment in a 
variety of ways. (Table)  Models have included mandatory government-run 
programs, such as those in France, and the Southern Swiss Canton of Ticino, 
non-profit voluntary systems such as the TOPS system in the UK, and private 
sector for profit vendors in the United States and Canada.  In a retrospective 
three-year study done by clinical researchers in Southern Switzerland, where 
there is a current register in place, repeat volunteerism in their registered 
population (N=1436) was only 0.2%.(4) This regional registry mandates a 
minimum of three-month drug-free interval.  A German survey of healthy 
volunteers (N=440) reported dual enrollment rate of ~3%.   In a US survey of 60 
subjects, ten percent admitted to being dually enrolled in studies.(2) The most 
common motivation in all these reports was financial.  In contrast, the North 
American registry provider IDI/Clinical RSVP reports a 12-18% rate of screening 
attempts before an appropriate wash out period. 
 
A potential argument against a central registry can be assessed in terms of 
justice, subject autonomy and cost.  The primary potential harm to subjects is 
that of loss of privacy.  For the governmentally mandated programs in locales 
with centralized medical care delivery, the risk of data breech is not significantly 
more than that associated with the standard delivery of medical care.  The UK 
and North American systems, which collect limited subject data, have even less 
potential risk for confidential data release.  Recent history of large-scale data 
breeches in various industries suggests that the potential for inadvertent release 
of clinical trial data private and governmental databases is equally likely.  The 
relative cost of administering a government-sponsored central registry can be 
viewed as an added cost to the clinical trial enterprise carried by society as a 
whole, or in a directed funding model, by the trial sponsors and research units.  
In the voluntary, private service model, the cost is borne by the users of the 
system.  However, as a primarily market-driven initiative, the value of a registry 
for sites and sponsors can be made on a business calculus of the relative cost of 
ensuring patient safety and trustworthy data.  In North America and the UK, 
subjects are free to limit participation to research sites that do not participate in 
central registries.  However, even in mandatory systems of France and Ticino, 
the use of a centralized registry is not coercive, and autonomy of subjects is 
maintained.  While the use of registries that collect even limited information may 
dissuade subject participation in studies, the practice does not impinge on the 
ability of subjects to make informed decisions about participation.  Indeed, the 
ability to volunteer in healthy volunteer studies is not a right.  By definition, 
potential subjects do not have a disease state for which treatment is needed.   
 
The third Belmont principal is that of beneficence.  Broadly stated, the questions 
are 1) is there a need to protect clinical trial subjects from themselves, and 2) is 
the subject’s attestation that they were not dually enrolled adequate evidence to 
ensure their protection?  The relative risks from loss of confidentiality are small, 
being equal or less to that associated with routine medical care.  The relative 
risks of dual enrolling to subjects are difficult to assess.  Despite the catastrophic 
TeGenero incident in 2006, in which healthy volunteers had grave injury during a 
first in human investigation of the drug TGN1412,, and a number of scattered 
individual events, on the whole participation in phase 1 clinical trials is not 
particularly dangerous.(5) While there are limited central data to make 
quantitative assessments of risk, participation in phase 1 studies according to 
study protocol almost certainly poses less risk than many accepted sources of 
income in our society such as police, fire fighters, and construction workers.  The 
poor evidentiary base of data makes an assessment of the additional risk from 
dual enrolling impossible to make with precision.  Accordingly, using standard 
methods to place a dollar cost per event prevented is not possible.  Against this 
backdrop of uncertainty however, it is in the interest of sponsors to conduct the 
best studies possible.  This includes not only the fiduciary duty to ensure high 
quality data, but also in making reasonable efforts to maximize the safety of 
subjects.  Stakeholders in this process include not only sponsors, but also 
contract research organizations and site investigators.  Subject education and 
systems to promote it will clearly not prevent all dual enrollment, but should be 
considered important elements of the informed consent process.  
 
The key question is whether the risk to subjects justifies the cost to the research 
enterprise (both private and public) of a mandatory registry.  Of note, the need for 
a registry has not been identified by the Department of Health and Human 
Services in the recently proposed overhaul of human subjects protection policies. 
We argue that the evidence of risk to subjects from occult dual enrolling is not 
high enough in relation to cost and to a lesser extent, potential loss of privacy, to 
warrant a mandatory system.  While it has been proposed that the FDA or NIH 
could administer a mandatory registry, neither organization has expressed an 
interest in pursuing this.  Establishing and maintaining a mandatory model would 
take resources, which in the current budgetary climate would involve moving 
funding from other core missions of these federal agencies.  There is, however, 
no ethical conflict with the establishment of a voluntary system to prevent dual 
enrollment.  A voluntary system is maximally efficient with dense adoption of a 
single registry, which prevents dual enrollers seeking research units without 
registry verification.  This could result in differential enrollment and adverse event 
patterns at otherwise comparable sites.  Non-sponsor owned sites, which choose 
to voluntarily participate in a registry, without explicit sponsor assumption of 
costs, also put themselves at competitive disadvantage when bidding for studies.  
In aggregate, however, a voluntary system has the benefit of spreading costs to 
the users of the system, as well as preserving the right of subjects to participate 
at research sites not participating in the system.  Modern evidence based 
medicine and drug development are based upon the use of high quality data to 
make cost benefit analysis.  While the lack of evidence of benefit of a phase 1 
subject registry should not prevent the phase 1 trial community from acting, the 
uniform institution of a mandate for subject registries is not yet supported by the 
extant data.   
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Table: Phase 1 Registries 
Database Who enrolls Exclusion/ 
washout 
period 
Data Collection 
 
Strengths /  
Benefits 
Weaknesses / 
Risks 
Multi-Site 
Viewing of 
Information? 
Cost Regulator 
Southern. 
Switzerland 
Regional 
Registry 
Healthy 
volunteers 
 
Site 
participation 
mandatory 
PI dependent, 
at least 3 
months  
 
Volunteer code 
(initials+ DOB + 
gender+ 
nationality), 
clinical research 
unit, study name, 
and date that 
subject’s allowed 
to participate 
again in another 
trial 
 
Data purge after 5 
yrs. 
If subject caught, 
they are excluded 
from all future 
studies. Only 
those involved 
with study can 
access 
information; no 
other sites. 
Subject identity 
protected on 
computer with no 
network access 
and alarm system. 
Subject cannot 
refuse to be on 
registry. 
 
 
No Government 
 
Financed by 
exam/appro
val 
fees~500 
Swiss 
Francs/stud
y 
Swiss 
National 
Science 
Foundation 
United 
Kingdom/ 
TOPS  
Healthy 
volunteers for 
Phase 1 trials. 
 
Site 
participation 
voluntary. 
Systemic drugs 
-  3 months 
min;  
-cannot receive 
> 10 milli-Sv 
of radioactivity 
in any 12-mo 
pd 
Unique ID 
(national 
insurance # or UK 
citizens or 
passport # at 
screening and the 
date of last dose 
of study drug 
 
Data purge after 2 
yrs. 
De-identified data. 
Site has flexibility 
with trials that 
have long follow 
up (>4wks). 
Simple, web-
based interphase  
Usernames and 
password protected 
by authorized users 
 
Input errors require 
calls to other sites 
to clarify 
participation 
history 
Web-based and 
all authorized 
CRUs can 
share/view if a 
subject has 
registered but not 
the last dose day 
(they must call 
the CRU) 
Registered 
non-profit 
organization  
 
Free to 
sites. 
The 
individual 
site and 
TOPS 
Administrat
ion 
France Subjects in 
whom research 
has no direct 
benefit 
 
Site 
participation 
PI dependent 
 
Code derived 
from subject’s 
names/DOB; 
start/end dates of 
study; end date of 
exclusion pd; $ 
compensation 
Data purge 1 year 
after the last date 
is entered.  
Based on annual 
salary ($4000 
annually). 
No protection 
against ID theft, 
privacy.  
 
All authorized 
research centers 
have direct 
access 
Government 
 
Public 
finance 
Ministry of 
Health 
PI = Principal Investigator; DOB = date of birth; TOPS = The Over volunteering Prevention System; CRU = clinical research unit.   
 
mandatory Subject must show 
proof of national 
health insurance 
USA & 
Canada/ 
ClincalRSVP  
Any subject 
who receives 
compensation 
for trial 
 
Site 
participation 
voluntary 
PI/study 
dependent 
 
Biometric data 
(finger print 
code), last dose 
 
Data purge after 5 
yrs. 
Subjects can 
dispute 
information 
entered into 
database if not 
accurate.  
 
Transparent 
tracking and 
auditing 
 
Limited collection 
of subject data. 
Voluntary basis 
allows subjects to 
seek non-
participating sites 
when dual enrolling 
 
Effectiveness 
reduced unless 
many sites in a 
region participate 
Sites can view 
only last date of 
study drug 
administration 
Private 
Sector 
 
Training + 
install = 
~$1500 
 
$40 per 
subject/stud
y 
Private 
corporation 
USA & 
Canada/ 
Verified 
Clinical 
Trials 
Any subject 
who receives 
compensation 
for trial 
 
Site 
participation 
voluntary 
PI/study 
dependent 
 
Web-based portal  Validity of subject 
identification 
checked against 
publically 
available 
databases 
Voluntary basis 
allows subjects to 
seek non-
participating sites 
when dual enrolling 
 
Effectiveness 
reduced unless 
many sites in a 
region participate 
Sites can view if 
subject is eligible  
$500 per 
study 
Private 
corporation 
